Literature DB >> 15123849

Cognitive function in patients with chronic granulomatous disease: a preliminary report.

Maryland Pao1, Edythe A Wiggs, Melissa M Anastacio, Jenny Hyun, Ellen S DeCarlo, Judi T Miller, Victoria L Anderson, Harry L Malech, John I Gallin, Steven M Holland.   

Abstract

Chronic granulomatous disease is an inherited immunodeficiency in which phagocytes fail to generate superoxide and its metabolites, resulting in severe recurrent infections and frequent hospitalizations. Chronic illness and frequent hospitalizations can affect growth and development as well as social and educational opportunities. Since no data have been reported on cognitive functioning in patients with this illness, the authors sought to examine cognitive function in a group of patients with chronic granulomatous disease. A retrospective chart review of 26 patients seen and followed at the National Institutes of Health who had received cognitive testing at the request of parent or staff was performed. Demographic information including medical, psychiatric, and developmental histories was gathered. Six patients (23%) were found to have an IQ of 70 or below, indicative of cognitive deficits, and all of those patients had defects in the membrane-linked cytochrome b558. The prevalence of cognitive deficits in this selected population of chronic granulomatous disease patients was high. The determination of the true distribution of cognitive functioning in the general chronic granulomatous disease population is important, since cognitive deficits have implications for educational planning and potential therapies such as transplantation and gene therapy in children.

Entities:  

Mesh:

Year:  2004        PMID: 15123849     DOI: 10.1176/appi.psy.45.3.230

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  30 in total

Review 1.  NADPH oxidases: novel therapeutic targets for neurodegenerative diseases.

Authors:  Hui-Ming Gao; Hui Zhou; Jau-Shyong Hong
Journal:  Trends Pharmacol Sci       Date:  2012-04-11       Impact factor: 14.819

2.  NOX activity in brain aging: exacerbation by high fat diet.

Authors:  Annadora J Bruce-Keller; Christy L White; Sunita Gupta; Alecia G Knight; Paul J Pistell; Donald K Ingram; Christopher D Morrison; Jeffrey N Keller
Journal:  Free Radic Biol Med       Date:  2010-03-25       Impact factor: 7.376

Review 3.  Sources and targets of reactive oxygen species in synaptic plasticity and memory.

Authors:  Kenneth T Kishida; Eric Klann
Journal:  Antioxid Redox Signal       Date:  2007-02       Impact factor: 8.401

Review 4.  Chronic granulomatous disease.

Authors:  Steven M Holland
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

Review 5.  New insights on NOX enzymes in the central nervous system.

Authors:  Zeynab Nayernia; Vincent Jaquet; Karl-Heinz Krause
Journal:  Antioxid Redox Signal       Date:  2014-01-16       Impact factor: 8.401

6.  NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1.

Authors:  Kenneth T Kishida; Maryland Pao; Steven M Holland; Eric Klann
Journal:  J Neurochem       Date:  2005-07       Impact factor: 5.372

Review 7.  Actin filaments-A target for redox regulation.

Authors:  Carlos Wilson; Jonathan R Terman; Christian González-Billault; Giasuddin Ahmed
Journal:  Cytoskeleton (Hoboken)       Date:  2016-08-06

8.  NADPH oxidases: molecular understanding finally reaching the clinical level?

Authors:  Tomasz J Guzik; Kathy K Griendling
Journal:  Antioxid Redox Signal       Date:  2009-10       Impact factor: 8.401

9.  NOX activity is increased in mild cognitive impairment.

Authors:  Annadora J Bruce-Keller; Sunita Gupta; Taryn E Parrino; Alecia G Knight; Philip J Ebenezer; Adam M Weidner; Harry LeVine; Jeffrey N Keller; William R Markesbery
Journal:  Antioxid Redox Signal       Date:  2010-06-15       Impact factor: 8.401

Review 10.  Chronic granulomatous disease.

Authors:  Steven M Holland
Journal:  Hematol Oncol Clin North Am       Date:  2012-11-22       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.